A Study to Assess the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG 016 Monotherapy in Patients With Advanced Solid Tumors
Clinical trial NCT05010525 · TERMINATED
Trial details
- NCT number
- NCT05010525
- Sponsor
- Shanghai Antengene Corporation Limited
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-09-01
- Primary completion
- 2022-11-14
- Enrollment
- 8
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.